Drexel University

Alliance Discovery, Inc.

Olimpia Meucci

Joseph M Salvino

Alessandro Fatatis

Whitney L Gladney

Fei Shen

Xin Feng

Whitney L Jamieson

The disclosure provides compounds of formula (II) having the structure: Compounds of formula (II) are fractalkine receptor agonists and useful in treating, preventing or minimizing metastasis in a subject diagnosed with cancer. The compounds of the disclosure are further useful in treating central nervous system diseases (such as, but not limited to, HIV Associated Neurocognitive Disorders (HAND), and/or Alzheimer's disease), pain, inflammation (such as, but not limited to, arthritis), cardiovascular disease (such as, but not limited to, undesired vascular smooth muscle proliferation, atherosclerosis, coronary vascular endothelial dysfunction, and/or coronary artery disease), and/or multiple sclerosis.

Substituted pyrrolo[1,2-α]quinoxalin-4(5H)-ones as CXCR1 antagonists

The disclosure provides compounds of formula (I) having the structure:  Compounds of formula (I) are fractalkine receptor agonists and useful in treating, preventing or minimizing metastasis in a subject diagnosed with cancer. The compounds of the invention are further useful in treating central nervous system diseases (such as, but not limited to, HIV Associated Neurocognitive Disorders (HAND), and/or Alzheimer's disease), pain, inflammation (such as, but not limited to, arthritis), cardiovascular disease (such as, but not limited to, undesired vascular smooth muscle proliferation, atherosclerosis, coronary vascular endothelial dysfunction, and/or coronary artery disease), and/or multiple sclerosis.

Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists

The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CXCR1 or fractalkine antagonist.

Compounds useful for inhibiting metastasis from cancer and methods using same

Methods of inhibiting metastasis from cancer

Growing community of inventors

Penn Valley, PA, United States of America

Olimpia Meucci